e-Drug3D

1436

LANREOTIDE

INN
LANREOTIDE

cas 108736-35-2

CLASS

HORMONES
SOMATOSTATIN ANALOG
LONG-TERM TREATMENT OF ACROMEGALIC PATIENTS
INHIBITOR OF VARIOUS ENDOCRINE, NEUROENDOCRINE, EXOCRINE AND PARACRINE FUNCTIONS
REDUCTION OF GH AND/OR IGF-1 LEVELS

ROUTE (list)

SUBCUTANEOUS

ATC code

H01CB03

PK parameters

F 78.4 PERCENT (120 MILLIGRAM)
Tmax 9.5 HOUR
VD 13 LITER (65 KILOGRAM)
Cl 23.7 LITER / HOUR
PPB 81 PERCENT
t1/2 636 HOUR

Target

TARGET SOMATOSTATIN RECEPTORS (SSTR) 2 AND 5
REDUCED BINDING AFFINITY FOR HUMAN SSTR1, 3, AND 4

DrugCentral

Somatostatin receptor type 2 UNIPROT P30874 SSTR2

Somatostatin receptor type 5 UNIPROT P35346 SSTR5

Download SDF file

L-Threoninamide, 3-(2-naphthalenyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-, cyclic (27)-disulfide

Formula:
C54H69N11O10S2

Calculated chemical properties:

MW 1096.34
NB_atoms 77
XLogP 0.82
PSA 305.776
NB_HD 16
NB_HA 21
fsp3 0.41
Lipinski(0=no;1=yes) 0

FDA
NDA 022074 (label) INN (LANREOTIDE ACETATE) SOMATULINE DEPOT (IPSEN PHARMA) APPROVAL= AP YEAR= 2007
NDA 215395 (label) INN (LANREOTIDE ACETATE) LANREOTIDE ACETATE (INVAGEN PHARMS) APPROVAL= AP YEAR= 2021
NDA 217193 (pdf not found) INN (LANREOTIDE ACETATE) LANREOTIDE ACETATE (INVAGEN PHARMS) APPROVAL= AP YEAR= 2024